Placebo News and Research

RSS

Treatment with MP-376 reduces P. aeruginosa in CF patients: Research

A new possible treatment to treat P. aeruginosa in cystic fibrosis patients appears to be promising, according to research to be presented at the ATS 2010 International Conference in New Orleans.

17 May 2010

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Long-term, regular use of vitamin E in women 45 years of age and older may help decrease the risk of chronic obstructive pulmonary disease by about 10 percent in both smokers and non-smokers, according to a study conducted by researchers at Cornell University and Brigham and Women's Hospital.

17 May 2010

Protox announces positive top-line results from the TRIUMPH study in first quarter 2010

Protox Therapeutics Inc. a leader in the development of receptor targeted fusion proteins, today released financial results for the first quarter 2010, ended March 31, 2010. "The first quarter of 2010 marked significant achievements for the company, namely the announcement of positive top-line results from the TRIUMPH study and the subsequent completion of a five million dollar financing," said Dr. Fahar Merchant, President and CEO of Protox.

15 May 2010

Report underscores need for additional research on diagnosis and treatment of food allergy

A review published Wednesday in the Journal of the American Medical Association and reported in the New York Times underscores the need for additional research on the prevalence, diagnosis, and treatment of food allergy. One of the most important points suggested by the JAMA study as well as a New York Times article on the subject is that as many as 1 in 10 people may have food allergy.

14 May 2010

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

The effects of multivitamins are most often researched in the elderly. This is one of very few studies to assess the relationship between supplementation with vitamins/minerals and psychological functioning in healthy groups of non-elderly adults. This study shows how a proprietary multivitamin and mineral supplement improves mood and mental performance while also reducing stress, mental tiredness and fatigue in healthy males.

14 May 2010

Nile Therapeutics reports net loss of $1.9M for first-quarter 2010

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced its first quarter financial results for 2010.

14 May 2010

Inhibitex reports net loss of $4.8M for first-quarter 2010

Inhibitex, Inc. today announced its financial results for the first quarter ended March 31, 2010. The Company also announced that it has initiated a Phase I single ascending dose trial of INX-189, its lead HCV nucleotide polymerase inhibitor, in healthy volunteers under an Investigational New Drug application with the U.S. Food and Drug Administration.

14 May 2010

International study to test effectiveness of celecoxib in preventing growth of precancerous polyps

Rush University Medical Center is testing whether celecoxib, known by its brand name Celebrex, can help prevent the growth of precancerous polyps that form in the colon, rectum and small intestine of children with an inheritable genetic disease called familial adenomatous polyposis.

14 May 2010

Report of 2009 H1N1 influenza VLP vaccine published online

Novavax, Inc. announces the first report of a vaccine protecting ferrets against the 2009 pandemic H1N1 virus has been published in the journal Vaccine May 12, 2010 online issue.

14 May 2010

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that clinical trial results on epratuzumab, the anti-CD22 humanized monoclonal antibody licensed to UCB SA, Brussels, for autoimmune disease indications, from the Phase IIb study in patients with lupus, will be presented in four posters sessions and one published abstract.

14 May 2010

Fibrocell Science commences histology study of azficel-T for treatment of nasolabial fold wrinkles

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced the initiation of a small histology study (IT-H-001) of azficel-T, an autologous cell therapy currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe nasolabial fold wrinkles.

14 May 2010

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

Daily consumption of probiotic cheese helps tackle age-related changes in immune system: Research

Scientists in Finland have discovered that cheese can help preserve and enhance the immune system of the elderly by acting as a carrier for probiotic bacteria. The research, published in FEMS Immunology & Medical Microbiology, reveals that daily consumption of probiotic cheese helps to tackle age-related changes in the immune system.

13 May 2010

Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up

Nearly one-third of patients with irritable bowel syndrome (IBS) who underwent a novel behavior treatment developed by a University at Buffalo behavioral scientist achieved significant relief within four weeks of beginning treatment.

13 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug.

13 May 2010

Scientists discover link between offspring lung function and maternal vitamin A supplementation

Vitamin A is critical to maternal health and child survival, yet in most developing countries Vitamin A deficiency is a leading cause of blindness and increased child mortality. The Johns Hopkins Bloomberg School of Public Health has long been a leader in vitamin A research, and scientists at the School recently discovered a link between offspring lung function and maternal vitamin A supplementation.

13 May 2010

$High dose Vitamin D linked to high rate of fractures and falls$

High dose Vitamin D linked to high rate of fractures and falls

Many women have been regularly taking vitamin D supplements in the hope that it is good for their bones. However a new study has shown that high doses of this vitamin can actually increase the number of falls and fractures in older women.

12 May 2010

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

BELLUS Health Inc. reported today its financial results for the first quarter ended March 31, 2010.

12 May 2010

Placebo News and Research

Treatment with MP-376 reduces P. aeruginosa in CF patients: Research

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Protox announces positive top-line results from the TRIUMPH study in first quarter 2010

Report underscores need for additional research on diagnosis and treatment of food allergy

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

Nile Therapeutics reports net loss of $1.9M for first-quarter 2010

Inhibitex reports net loss of $4.8M for first-quarter 2010

International study to test effectiveness of celecoxib in preventing growth of precancerous polyps

Report of 2009 H1N1 influenza VLP vaccine published online

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Fibrocell Science commences histology study of azficel-T for treatment of nasolabial fold wrinkles

Chimerix commences first-in-human study of CMX157 for HIV

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Daily consumption of probiotic cheese helps tackle age-related changes in immune system: Research

Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Scientists discover link between offspring lung function and maternal vitamin A supplementation

High dose Vitamin D linked to high rate of fractures and falls

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News